PLUSPAK

Features & Benefits

The GE Healthcare polymer bottle is called
+PLUSPAK for a reason. This breakthrough in packaging has many exciting pluses! It includes a pull ring for easy access, plus peel-off tracking labels for convenient documentation, plus a latex-free bull's-eye stopper. All the pluses add up to a new level of convenience and safety.

Easy-to-open cap

  • Pull-ring provides easy access to contrast media.
  • Bull's-eye stopper provide easy stylet or spiking access

Polypropylene

  • Pharmaceutical-grade polymer construction makes it unbreakable, helping to prevent accidents and contrast media waste

Latex-free

  • The latex-free bull's-eye stopper and bottle eliminate risk of latex-sensitivity reactions

Peel-off tracking label

  • Peel-off tracking labels allow more convenient and accurate product documentation
  • Peel-off tracking label help comply with the Joint Commission on Acreditation of Healthcare Organizations (JCAHO) standards in Labeling and National Patient Safety Goals

Hanger

  • Integrated hanger makes hanging bottle simple and convenient

100 mL Pharmacy Bulk Package

  • Provides convenience when drawing multiple single doses (See Pharmacy Bulk Package Prescribing Information for proper use)
  • Helps reduce contrast media waste when dosing by weight

WARNING: NOT FOR INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

NOT FOR INTRATHECAL USE
Inadvertent intrathecal use of OMNISCAN has caused convulsions, coma, sensory and motor neurologic deficits.

NSF
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis in patients with acute or chronic severe renal insufficiency (glomerular filtration rate <30mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration.


The most frequent adverse events during OMNISCAN clinical trials in 1,369 patients, at doses between 0.025 and 0.3 mmol/kg, were headache, dizziness, and nausea. The majority of these adverse events were of mild to moderate intensity. The possibility of a reaction, including serious, life-threatening, fatal anaphylactoid, or cardiovascular reactions, or other idiosyncratic reaction, should always be considered, especially in those patients with a known clinical hypersensitivity. Refer to the boxed warning and warning section of the package insert for acute or chronic renal insufficiency since OMNISCAN is cleared from the body by glomerular filtration. Patients with a history of allergy or drug reaction should be observed for several hours after administration.